The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2016Patient-Carer-Provider Communication about the Impact of Motor and Non-motor Fluctuations
Study Rationale:
Temporary periods of poor mobility and other symptoms (OFF periods) are common in Parkinson’s disease and are associated with poorer quality of life. OFF symptoms are complex, with... -
Improved Biomarkers and Clinical Outcome Measures, 2016Developing New Method for GBA sequencing and Detection of Germ-line or Somatic Point Mutations, Deletion/Insertions and Recombinations with the GBA Pseudo Gene
Study Rationale:
Mutations in the GBA gene are the most common genetic cause of Parkinson’s disease. This gene has a nearby pseudogene, which is a genetic material that is very...
-
Improved Biomarkers and Clinical Outcome Measures, 2016Supramolecular Hosts as Combined Protein Aggregation Inhibitors and Hyperpolarized MRI Reporters
Study Rationale:
Amyloid fibrils play a key role in Parkinson's disease (PD) and monitoring of their formation from self‐assembled insoluble molecular aggregates would be extremely valuable as a... -
Access to Data and Biospecimens, 2016Evaluation of Glucocerebrosidase Pathway Biomarkers in Parkinson's Disease
Study Rationale:
Parkinson disease (PD) due to monoallelic glucocerebrosidase (GBA1) gene mutations (GBA-PD) is at the forefront of novel approaches to the treatment of PD. Exciting potential...
-
Research Grant, 2016Identification of Epigenetic Signatures in Blood as Biomarkers for Parkinson's Disease
Study Rationale:
Epigenetic processes (changes in gene expression), such as DNA methylation (mechanism that cells use to control gene expression), ensure proper functioning of genetic materials in... -
Biomarker Development, 2015Development of Novel, Small Molecule Compounds as PET Tracers for Synucleinopathies
Study Rationale:
Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson’s disease (PD) pathology. Such an agent will help (i) diagnose PD earlier,...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.